

HRT Treatment Selector

Charts revised July 2019. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV	MVC	BIC/ F/TAF	DTG	EVG/c/ F/TAF	EVG/c/ F/TDF	RAL	ABC	FTC or 3TC	F/TAF	TDF	ZDV
Estrogens																					
Estradiol	↑ ^a	↓ ^b	↑ ^a	↓ ^b	↓ ^b	↔	↓ ^b	↓ ^b	↓ ^b	↔	↔	↔	↔	↑ ^a	↑ ^a	↔	↔	↔	↔	↔	↔
Progestins (HRT)																					
Drospirenone	↑ ^{a,c}	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↔	↓ ^b	↓ ^b	↓ ^b	↔	↔	↔	↔	↑ ^a	↑ ^a	↔	↔	↔	↔	↔	↔
Dydrogesterone	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↔	↓ ^b	↓ ^b	↓ ^b	↔	↔	↔	↔	↑ ^a	↑ ^a	↔	↔	↔	↔	↔	↔
Levonorgestrel	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↔	↓ ^b	↓ ^b	↓ ^b	↔	↔	↔	↔	↑ ^a	↑ ^a	↔	↔	↔	↔	↔	↔
Medroxy- progesterone (oral)	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↔	↓ ^b	↓ ^b	↓ ^b	↔	↔	↔	↔	↑ ^a	↑ ^a	↔	↔	↔	↔	↔	↔
Norethisterone (Norethindrone)	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↔	↓ ^b	↓ ^b	↓ ^b	↔	↔	↔	↔	↑ ^a	↑ ^a	↔	↔	↔	↔	↔	↔
Norgestrel	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↔	↓ ^b	↓ ^b	↓ ^b	↔	↔	↔	↔	↑ ^a	↑ ^a	↔	↔	↔	↔	↔	↔

Colour Legend

	No clinically significant interaction expected.
	These drugs should not be coadministered.
	Potential interaction which may require a dose adjustment or close monitoring.
	Potential interaction predicted to be of weak intensity. No <i>a priori</i> dosage adjustment is recommended.

Text Legend

- ↑ Potential increased exposure of the hormone
- ↓ Potential decreased exposure of the hormone
- ↔ No significant effect

Notes

- a The clinical significance of increased exposure in terms of overall risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women receiving substitution hormones is unknown.
- b Monitor for signs of estrogen deficiency.
- c Coadministration is contraindicated in the US product label due to the potential for hyperkalaemia. The European product label recommends clinical monitoring for hyperkalaemia.